Valued at USD 6.51 billion in 2025, the global AI in oncology market is projected to reach USD 8.26 billion in 2026 and USD 56.44 billion by 2034, growing at a CAGR of 27.1% during the forecast period 2026–2034. Growing demand for early diagnosis and personalized treatment planning is fueling adoption. Prominent players include Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies, and PathAI. This article reviews the clinical applications and data capabilities that B2B stakeholders should monitor.

Cancer Burden Driving the AI in Oncology Market

According to the WHO, as cited in the report, cancer is the primary cause of death globally, accounting for nearly one in six deaths, or about 10 million people. Lung cancer contributed most of these deaths, with 2.2 million cases and 1.8 million deaths in 2020. This burden, together with shortages of healthcare professionals, is driving adoption of AI to deliver efficient, accurate diagnoses and treatments. The pandemic also spurred demand, as movement restrictions in hospitals and homecare settings complicated diagnosis, care, and treatment and increased the need for solutions in remote locations.

Traditional Oncology versus AI-Powered Oncology

The report contrasts traditional oncology, which relies on manual image analysis and guideline-based decisions, with AI-powered approaches that use automated data processing for faster detection, identify subtle patterns in imaging, pathology, and molecular data, and enable patient-specific treatment through genomic, clinical, and real-time data. AI also automates data analysis, reporting, and decision support to improve clinical workflows. Traditional approaches offer limited ability to forecast disease progression and treatment response, whereas AI supports earlier intervention and improved patient monitoring.

Immunotherapy Gains Momentum

The immunotherapy segment is expected to grow at a substantial pace, driven by positive clinical outcomes demonstrating high efficacy and an increasing number of approvals. In January 2023, a new AI-based biomarker was introduced to help predict immunotherapy response in lung cancer patients. A ScienceDirect article cited in the report indicates that AI can identify major histocompatibility complex patterns with 91.66% accuracy in predicting immunotherapy response. The report adds that incorporating AI enhances the accuracy of immunotherapy.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/ai-in-oncology-market

Brain Tumor Diagnostics Show Rapid Growth

The brain tumor segment is expected to grow rapidly. AI combined with advanced imaging supports accurate diagnoses of brain tumors during surgery within about three minutes by distinguishing tumors from healthy tissue, and various deep learning models are proving beneficial for neurologists, according to the report. The segment's momentum shows AI and advanced imaging expanding intraoperative diagnostic capability.

Predictive Analytics and Genomic Analysis

Increasing integration of AI with genomic analysis and drug discovery will create new market opportunities, while adoption of AI-based predictive analytics is expected to improve patient monitoring, prognosis, and treatment outcomes. Compared with traditional approaches, predictive analytics estimates cancer risks, outcomes, and therapy effectiveness. Advances in deep learning, machine learning, and genomic analytics are enhancing cancer detection, diagnosis, and therapy selection.

Clinical Decision Support and Adoption Barriers

AI-powered software is used for clinical decision support alongside diagnosis, treatment planning, and medical imaging analysis. Growth in AI-powered imaging systems and cloud-based oncology platforms is improving accessibility, collaboration, and clinical decision-making. Barriers persist: data privacy concerns, regulatory challenges, and limited access to high-quality clinical datasets restrain adoption, and stringent regulation of AI-enabled products, high costs, and workforce displacement concerns add pressure.

Competitive Landscape and Recent Developments

In June 2026, the National Cancer Center launched a research initiative focused on AI technology that can predict the likelihood of success for drug candidates before they enter the expensive, time-consuming drug development process. North America held 42.8% of revenue in 2025, and Asia Pacific is projected to post the highest CAGR at 32.4%. Company coverage in the report includes Azra AI and Siemens Healthcare GmbH, among others.

Outlook for the AI in Oncology Market

Surging investment in AI-driven cancer research and targeted therapies positions AI as a transformative force in global AI in oncology care.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market